Centers for Disease Control and Prevention
Model Performance Evaluation Program
Human T-Lymphotropic Virus Types I and II
(HTLV-I/II) Testing

Figures Used for the
Analysis of the May 5, 1997 Testing Results
Reported by Participant Laboratories

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control and Prevention
Public Health Practice Program Office
Division of Laboratory Systems
Atlanta, Georgia 30333

Report of the May 5, 1997 Human T-lymphotropic virus types I and II (HTLV-I/II) Performance Evaluation Sample Testing Results Provided by Participant Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

The production of this report was coordinated in CDC by:

Public Health Practice Program Office.....Edward L. Baker, M.D., M.P.H., Director
Division of Laboratory Systems..... ...Carlyn L. Collins, M.D., M.P.H., Director
Laboratory Practice Assessment Branch.....Thomas L. Hearn, Ph.D., Chief

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP).....William O. Schalla, M.S., Chief
MPEP HTLV Performance Evaluation.....Laurina O. Williams, Ph.D.
HTLV Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-4678 or (770) 488-4366.

Centers for Disease Control and Prevention (CDC)
Model Performance Evaluation Program
Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing
May 5, 1997 Participant Laboratory Shipment

Table 1

Panel Letter	Vial Label	CDC Donor Number	CDC Contractor Result[2]	Laboratory Interpretation[1]			
				INIT.[3]	FINAL[4]	WB	IIF
A	A1	13	Negative	___	___	___	___
	A2,A6	09	Negative	___	___	___	___
	A3,A5	05	Positive	___	___	___	___
	A4	01	Positive	___	___	___	___
B	B1,B3	10	Negative	___	___	___	___
	B2	14	Negative	___	___	___	___
	B4,B6	06	Positive	___	___	___	___
	B5	02	Positive	___	___	___	___
C	C1,C5	07	Positive	___	___	___	___
	C2,C4	11	Negative	___	___	___	___
	C3	15	Negative	___	___	___	___
	C6	03	Positive	___	___	___	___
D	D1	04	Positive	___	___	___	___
	D2,D6	08	Positive	___	___	___	___
	D3,D5	12	Negative	___	___	___	___
	D4	16	Negative	___	___	___	___

[1] Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.

[2] The CDC result was obtained after composite EIA, WB, and RIPA testing, by CDC contractor, and employing the interpretation criteria of the Public Health Service Working Group.

[3] Initial EIA interpretation

[4] Final EIA interpretation

SUPPLEMENTAL INFORMATION FOR COMPREHENDING THE NUMBERS USED TO LABEL FIGURES IN THIS REPORT

The "N=" that appears on each graph represents the number of laboratories that reported results. For some graphs, laboratories reported results using more than one test; therefore, the number of results may exceed the actual number of laboratories providing reports. In figures 1-7, the vertical axis is labeled either as frequency or percentage of results; in figures 8 and 9, this axis is labeled as percentage of reports. However, in all figures, the number appearing directly above or within each bar represents a frequency of results only.

Figure 1. Frequency of HTLV-I/II antibody test result interpretations, by sample type (reactivity), for enzyme immunoassay (EIA), Western blot (WB), and indirect immunofluorescence (IIF), reported by participant laboratories for the May 5, 1997 shipment



* = Indeterminate is not an EIA interpretation option; these areas have been left blank





Figure 2. Percentage of HTLV-I/II participant laboratories, by laboratory type, that reported EIA, WB, and IIF results to the CDC for the May 5, 1997 shipment



Figure 3. Combination of HTLV-I/II antibody tests reported by participant laboratories for the May 5, 1997 shipment



Figure 4. Types of HTLV-I/II antibody test kits used for enzyme immunoassay, Western blot, and indirect immunofluorescence, as reported by participant laboratories to the CDC for the May 5, 1997 shipment







Figure 5. Enzyme immunoassay HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 5, 1997 shipment





Test Result Interpretations

Non-Reactive Reactive

CDC Model Performance Evaluation Program
HTLV-I/II Antibody Testing

Figure 6. Western blot HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 5, 1997 shipment



Figure 7. Indirect immunofluorescence HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 5, 1997 shipment



Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by participant laboratories for the May 5, 1997 shipment



CDC Model Performance Evaluation Program
HTLV-I/II Antibody Testing

Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by participant laboratories for the May 5, 1997 shipment



Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by participant laboratories for the May 5, 1997 shipment



Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by participant laboratories for the May 5, 1997 shipment



Figure 10. Types of 'Other' HTLV antibody test kits used and results reported by participant laboratories to the CDC for the May 5, 1997 shipment







Test Result Interpretations

Non-Reactive Indeterminate Reactive

CDC Model Performance Evaluation Program
HTLV-I/II Antibody Testing